First psychedelic therapy enters EMA PRIME scheme, a potential turning point for Europe
A psychedelic compound, bretisilocin, has entered the European Medicines Agency’s PRIME (Priority Medicines) scheme for the treatment of major depressive disorder. This marks a notable development for psychedelic research and regulatory engagement in Europe.
PRIME is designed to support the development of medicines that may address unmet medical needs. It offers early and continuous interaction with regulators throughout development and the enhanced use of regulatory instruments, including the possibility of accelerated assessment at later stages. Just yesterday, after a two-year pilot, the EMA announced the launch of three new tools to assist developers within the PRIME scheme. While not an approval pathway, it is widely considered the closest European equivalent to the U.S. FDA’s Breakthrough Therapy Designation.
Psychiatry has so far had a very limited presence within PRIME compared to other therapeutic areas such as oncology. In contrast, the United States has seen seven FDA Breakthrough Therapy designations for psychedelic treatments. This makes the inclusion of a psychedelic programme in Europe particularly relevant in the current landscape of mental health innovation.
Bretisilocin, originally developed by Gilgamesh Pharmaceuticals and now owned by AbbVie, is described as a short-acting serotonin (5-HT) 2A receptor agonist and 5-HT releaser, producing a relatively short psychoactive experience. It is currently in Phase 2 clinical development for major depressive disorder. Its entry into PRIME suggests that early data may be considered sufficiently promising to warrant closer regulatory support.
The development comes at a time when mental health and unmet medical need are gaining increased attention within the revision of EU pharmaceutical legislation. PAREA has been actively advocating for stronger recognition of mental health innovation within this framework.
EMA leadership has also encouraged developers of psychedelic therapies to engage earlier with European regulators and to make use of available pathways such as PRIME. Early dialogue is seen as key to aligning development strategies with regulatory expectations in Europe.
While significant uncertainties remain, including the need for robust late-stage clinical data, regulatory review, and national-level decisions on reimbursement and delivery, this milestone may signal the beginning of a more active role for Europe in psychedelic drug development and, ultimately, patient access.
